# BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.

> **NCT03867942** · PHASE1 · UNKNOWN · sponsor: **LG Chem** · enrollment: 48 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Dyslipidemias

## Interventions

- **DRUG:** Monolayer group
- **DRUG:** Bilayer group

## Key facts

- **NCT ID:** NCT03867942
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-21
- **Primary completion:** 2019-05-24
- **Final completion:** 2019-08-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2019-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03867942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03867942, "BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03867942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*